These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16759055)

  • 1. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
    Borroto-Esoda K; Vela JE; Myrick F; Ray AS; Miller MD
    Antivir Ther; 2006; 11(3):377-84. PubMed ID: 16759055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
    Muñoz de Benito RM; Arribas López JR
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
    Ray AS; Myrick F; Vela JE; Olson LY; Eisenberg EJ; Borroto-Esodo K; Miller MD; Fridland A
    Antivir Ther; 2005; 10(3):451-7. PubMed ID: 15918336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.
    Kulkarni R; Feng JY; Miller MD; White KL
    Antiviral Res; 2014 Jan; 101():131-5. PubMed ID: 24291780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.
    Feng JY; Ly JK; Myrick F; Goodman D; White KL; Svarovskaia ES; Borroto-Esoda K; Miller MD
    Retrovirology; 2009 May; 6():44. PubMed ID: 19439089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.
    Venhoff N; Setzer B; Melkaoui K; Walker UA
    Antivir Ther; 2007; 12(7):1075-85. PubMed ID: 18018766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
    Zhu Y; Curtis M; Qi X; Miller MD; Borroto-Esoda K
    Antivir Chem Chemother; 2009; 19(4):165-76. PubMed ID: 19374144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On-line coupling of anion exchange and ion-pair chromatography for measurement of intracellular triphosphate metabolites of reverse transcriptase inhibitors.
    Kuklenyik Z; Martin A; Pau CP; Holder A; Youngpairoj AS; Zheng Q; Cong ME; Garcia-Lerma JG; Heneine W; Pirkle JL; Barr JR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(29):3659-66. PubMed ID: 19783232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
    Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro interactions between apricitabine and other deoxycytidine analogues.
    Bethell R; De Muys J; Lippens J; Richard A; Hamelin B; Ren C; Collins P
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2948-53. PubMed ID: 17517847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.
    Uglietti A; Zanaboni D; Gnarini M; Maserati R
    Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1305-14. PubMed ID: 22943210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of the acyclic nucleoside phosphonate tenofovir toward human T-cell leukemia/lymphotropic virus type 1 infection of human peripheral blood mononuclear cells in vitro.
    Balestrieri E; Sciortino MT; Mastino A; Macchi B
    Antiviral Res; 2005 Dec; 68(3):154-62. PubMed ID: 16271772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.
    Bonora S; Gonzalez de Requena D; D'Avolio A; Calcagno A; Tettoni M; Siccardi M; Baietto L; Simiele M; Trentini L; Di Perri G
    Antivir Ther; 2011; 16(4):499-504. PubMed ID: 21685537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro.
    Drogan D; Rauch P; Hoffmann D; Walter H; Metzner KJ
    Antiviral Res; 2010 Jun; 86(3):312-5. PubMed ID: 20302887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
    Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P
    Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
    Marchand B; White KL; Ly JK; Margot NA; Wang R; McDermott M; Miller MD; Götte M
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2911-9. PubMed ID: 17517852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HIV-1 replication in macrophages by a heterodinucleotide of lamivudine and tenofovir.
    Rossi L; Franchetti P; Pierigé F; Cappellacci L; Serafini S; Balestra E; Perno CF; Grifantini M; Caliò R; Magnani M
    J Antimicrob Chemother; 2007 Apr; 59(4):666-75. PubMed ID: 17327293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination.
    Schader SM; Colby-Germinario SP; Schachter JR; Xu H; Wainberg MA
    AIDS; 2011 Aug; 25(13):1585-94. PubMed ID: 21633286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.